Table 3. Best overall response in first-line treatment according to MMR status.
| Patients evaluable for response | pMMR (n=453) | dMMR MLH1-hypermethylation (n=12) | dMMR total (n=16) | P-value# pMMR vs dMMR hypermethylation | P-value# pMMR vs dMMR total |
|---|---|---|---|---|---|
| Best overall response | |||||
| Complete response | 16 (4%) | — | — | ||
| Partial response | 123 (27%) | 4 (33%) | 4 (25%) | ||
| Stable disease | 235 (52%) | 3 (25%) | 5 (31%) | ||
| Progressive disease | 79 (17%) | 5 (42%) | 7 (44%) | ||
| Response rate (95% CI) | 31% (27–35%) | 33% (10–65%) | 25% (7–52%) | 0.84 | 0.63 |
| n=139 | n=4 | n=4 | |||
| Disease control (95% CI) | 83% (79–86%) | 58% (28–85%) | 56% (30–80%) | 0.031 | 0.008 |
| n=374 | n=7 | n=9 | |||
| Sequential treatment | n=239 | n=5 | n=8 | ||
| Response rate (95% CI) | 17% (13–23%) | 40% (5–85%) | 25% (3–65%) | 0.19 | 0.57 |
| n=41 | n=2 | n=2 | |||
| Disease control (95% CI) | 76% (70–81%) | 60% (15–95%) | 50% (16–84%) | 0.40 | 0.09 |
| n=182 | n=3 | n=4 | |||
| Combination treatment | n=214 | n=7 | n=8 | ||
| Response rate (95% CI) | 46% (39–53%) | 29% (4–71%) | 25% (3–65%) | 0.46 | 0.30 |
| n=98 | n=1 | n=2 | |||
| Disease control (95% CI) | 90% (85–93%) | 57% (18–90%) | 63% (25–92%) | 0.033 | 0.048 |
| n=193 | n=4 | n=5 | |||
#P-value χ2.